It simply works
Since the benefits of tight glycaemic control early in the disease are well documented, and sustained weight loss is recognised as an important goal in those with obesity and type 2 diabetes, the authors argue that guidelines may need to change to harness the potential benefits of tirzepatide, other incretin co-agonists and other combination drugs in development
Seek urgent medical help if your blood glucose remains below 4.0 mmol/L after two treatments, if it falls below 3.0 mmol/L with symptoms, or if you become unconscious
Understanding the appropriate steps when doses are delayed helps ensure safe, effective treatment whilst minimising potential side effects
If lipohypertrophy develops from poor rotation habits, you may need to increase your dose earlier than expected to achieve the same effectwhich costs more and introduces unnecessary complexity
GLP-1 medicines available in India in 2026 Two molecules dominate: semaglutide (a GLP-1 agonist) and tirzepatide (a dual GIP/GLP-1 agonist)